Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 11,250 Shares

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $74.40, for a total value of $837,000.00. Following the sale, the chief financial officer now directly owns 41,098 shares of the company’s stock, valued at approximately $3,057,691.20. This represents a 21.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $73.82 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The stock’s 50-day moving average is $71.48 and its two-hundred day moving average is $71.51. The firm has a market cap of $43.40 billion, a P/E ratio of 10.59, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period in the prior year, the firm posted $0.66 EPS. The business’s revenue was up 6.2% compared to the same quarter last year. Analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Barclays upped their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Wolfe Research downgraded Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $79.45.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Vega Investment Solutions bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. Rossby Financial LCC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $29,000. Finally, Costello Asset Management INC bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth about $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.